OXB.L

Oxford Biomedica Plc
Oxford Biomedica PLC - Grant of Options
4th October 2024, 14:25
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0535H
Oxford Biomedica PLC
04 October 2024
 

 

Grant of options

 

Oxford, UK - 04 October 2024: Oxford Biomedica plc ("OXB" or the "Company"; LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that on 03 October 2024 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the OXB 2024 Long Term Incentive Plan ("LTIP").

 

2024 LTIP Awards

 

Name of individual

Title

Number of shares subject to the DBP/LTIP award prior to 2024 award

Number of shares subject to the 2024 LTIP award

Total shares over which options now held

Percentage of current issued share capital under option

Frank Mathias

Chief Executive Officer

323,178

257,113

580,291

0.55%

Lucinda Crabtree

Chief Financial Officer

-

170,113

170,113

0.16%

Sebastien Ribault

Chief Business Officer

66,903

58,406

125,309

0.12%

Thierry Cournez

Chief Operating Officer

66,437

51,570

118,007

0.11%

Lisa James

Chief People Officer

99,989

40,464

140,453

0.13%

Kyriacos Mitrophanous

Chief Innovation Officer

179,433

52,651

232,084

0.22%

Natalie Walter

Group General Counsel and Company Secretary

152,818

49,169

201,987

0.19%

 

In line with best practice, the award granted to Frank Mathias was scaled back from 200% of salary to 160% of salary, with the same proportionate scale back applied to below board grantees. As a newly appointed Director, Lucinda Crabtree's award was scaled back from 175% of salary to 157.5% of salary.

The Remuneration Committee has determined that EBITDA margin and revenue growth are the key metrics aligned with the growth strategy. Therefore, for this grant the performance conditions will be based on those metrics, weighted 40% EBITDA margin and 60% revenue growth, with no non-financial leading performance indicators metrics. Performance in respect of each measure will be assessed following the end of a three year performance period ending with 2026. Details of the targets for the EBITDA margin and revenue growth measures are included in the 2023 Directors' Remuneration Report.

The awards will "vest" on 3 October 2027 to the extent determined by reference to the assessment of the performance condition. The awards granted to Frank Mathias and Lucinda Crabtree will only be "released" so that they can be exercised following the end of a further two year holding period. The awards granted to other participants will be released at vesting.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Frank Mathias

2.

Reason for the notification

a)

Position/status

Chief Executive Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2024 LTIP Award

 

Price

Volume

Nil

257,113

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 257,113 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Lucinda Crabtree

2.

Reason for the notification

a)

Position/status

Chief Financial Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2024 LTIP Award

 

Price

Volume

Nil

170,113

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 170,113 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Sebastien Ribault

2.

Reason for the notification

a)

Position/status

Chief Business Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2024 LTIP Award

 

Price

Volume

Nil

58,406

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 58,406 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Thierry Cournez

2.

Reason for the notification

a)

Position/status

Chief Operating Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2024 LTIP Award

 

Price

Volume

Nil

51,570

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 51,570 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Lisa James

2.

Reason for the notification

a)

Position/status

Chief People Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2024 LTIP Award

 

Price

Volume

Nil

40,464

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 40,464 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Kyriacos Mitrophanous

2.

Reason for the notification

a)

Position/status

Chief Innovation Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2024 LTIP Award

 

Price

Volume

Nil

52,651

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 52,651 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

 

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Natalie Walter

2.

Reason for the notification

a)

Position/status

General Counsel

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2024 LTIP Award

 

Price

Volume

Nil

49,169

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 49,169 shares in total

 

 

N/A

 

e)

Date of the transaction

2024-10-03

f)

Place of the transaction

Outside of trading venue

 

 

-Ends-

 

Enquiries:       

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About OXB

 

OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZMGGDDMGDZM]]>
TwitterFacebookLinkedIn